Xevudy Helps GSK Ride Out Depressed Shingrix Sales

But COVID-19 Profits Will Drop In 2022

 
• By Andrew McConaghie
  
GSK
The pharma and vaccines-focused New GSK will emerge in mid-2022, and investors want to see an improved growth trajectory. • Source: Alamy

More from Earnings

More from Business